Apadamtase alfa

From WikiMD's WELLNESSPEDIA

(Redirected from Adzynma)

Apadamtase alfa is a biopharmaceutical product that is currently under development. It is a type of enzyme replacement therapy that is being studied for its potential use in the treatment of certain genetic disorders.

Overview[edit]

Apadamtase alfa is a recombinant form of the human enzyme adamts13. This enzyme plays a crucial role in the regulation of blood clotting, and deficiencies in this enzyme can lead to serious health conditions such as thrombotic thrombocytopenic purpura (TTP), a rare blood disorder.

Mechanism of Action[edit]

The primary function of the ADAMTS13 enzyme is to cleave von Willebrand factor (vWF), a protein that is essential for platelet adhesion. In individuals with a deficiency in ADAMTS13, vWF molecules can accumulate and lead to the formation of abnormal blood clots. Apadamtase alfa works by replacing the deficient ADAMTS13 enzyme, thereby restoring the normal cleavage of vWF and preventing the formation of these abnormal clots.

Clinical Development[edit]

Apadamtase alfa is currently in the clinical development stage. Early phase clinical trials have shown promising results, with patients demonstrating improved ADAMTS13 activity and a reduction in the frequency of TTP episodes. However, further research is needed to fully understand the long-term safety and efficacy of this treatment.

Potential Applications[edit]

If approved, apadamtase alfa could provide a new treatment option for patients with ADAMTS13 deficiency and related conditions. This could potentially include not only patients with TTP, but also those with other conditions that are associated with abnormal blood clotting, such as stroke and heart attack.

See Also[edit]


<img src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Searchtool.svg/40px-Searchtool.svg.png" alt="Stub icon" width="40" height="40" /> This biopharmaceutical related article is a stub. You can help WikiMD by expanding it.
This article is a stub related to genetics. You can help WikiMD by expanding it!



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.